{"disease":{"id":"heparin-induced-thrombocytopenia","name":"heparin induced thrombocytopenia"},"drugs":{"marketed":[{"drug_id":"argatroban","indication_name":"Thrombosis Prevention in Heparin-Induced Thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Argatroban","generic_name":"ARGATROBAN","company_name":"Hikma Pharm Co Ltd","drug_phase":"marketed","molecular_target":"Prothrombin","drug_class":"Anti-coagulant [EPC]","quality_score":63,"revenue":null,"mechanism":"Argatroban works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"argatroban","indication_name":"Thrombosis in Heparin Induced Thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Argatroban","generic_name":"ARGATROBAN","company_name":"Hikma Pharm Co Ltd","drug_phase":"marketed","molecular_target":"Prothrombin","drug_class":"Anti-coagulant [EPC]","quality_score":63,"revenue":null,"mechanism":"Argatroban works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"lepirudin","indication_name":"Thrombosis in Heparin Induced Thrombocytopenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Refludan","generic_name":"LEPIRUDIN","company_name":"","drug_phase":"marketed","molecular_target":"Prothrombin","drug_class":"Anti-coagulant","quality_score":35,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03269019","title":"Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Wuhan Asia Heart Hospital","has_results":false},{"nct_id":"NCT06066762","title":"Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05783895","title":"Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT04782843","title":"Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.","phase":"","overall_status":"UNKNOWN","enrollment_count":124,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT03147638","title":"Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Marshall University","has_results":false},{"nct_id":"NCT03979625","title":"Prognosis Related to Induced Thrombopenia With Heparin Under Venoarterial ECMO in Reanimation","phase":"","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05785819","title":"A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"Veralox Therapeutics","has_results":false},{"nct_id":"NCT04751357","title":"Argatroban Monitoring in Critically Ill Patients: Evaluation of a Novel Ecarin-based Bedside Test","phase":"","overall_status":"UNKNOWN","enrollment_count":21,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT05586854","title":"Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Ramsay Générale de Santé","has_results":false},{"nct_id":"NCT05325346","title":"A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Veralox Therapeutics","has_results":false},{"nct_id":"NCT03809481","title":"Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Aspen Global Incorporated","has_results":false},{"nct_id":"NCT03594045","title":"Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Massachusetts General Hospital","has_results":true}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}